Premium
Paclitaxel‐releasing mesenchymal stromal cells inhibit the growth of multiple myeloma cells in a dynamic 3D culture system
Author(s) -
Bonomi Arianna,
Steimberg Nathalie,
Benetti Anna,
Berenzi Angiola,
Alessandri Giulio,
Pascucci Luisa,
Boniotti Jennifer,
Coccè Valentina,
Sordi Valeria,
Pessina Augusto,
Mazzoleni Giovanna
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2306
Subject(s) - mesenchymal stem cell , multiple myeloma , bone marrow , stromal cell , cancer research , paclitaxel , in vivo , medicine , in vitro , cancer , immunology , biology , pathology , microbiology and biotechnology , biochemistry
Multiple myeloma is an aggressive tumour able to suppress osteoblastogenesis probably mediated by bone marrow mesenchymal stromal cells (BM‐MSCs) that can also support plasma cell growth/survival. The use of MSCs for multiple myeloma therapy is a controversial topic because of the contradictory results on the capacity of MSCs to inhibit or to promote cancer growth. Our previous studies demonstrated that MSCs could be loaded with Paclitaxel (PTX) and used to deliver the drug in situ in amount affecting tumour growth ( in vitro and in vivo) . Therefore, independently on the discussed action of MSCs in myeloma, MSCs could represent a ‘trojan horse’ to vehicle and deliver anti‐tumour agents into bone marrow. This study confirms, by an in vitro 3D dynamic culture system, that PTX loaded BM‐MSCs (PTXr‐MSCs) are active on the proliferation of RPMI 8226, a human myeloma cell line. Our results demonstrated a dramatic suppression of myeloma cell growth by PTXr‐MSCs, suggesting that drug loaded MSCs could be a tool to deliver drug into the bone marrow. Drug releasing MSCs provide a therapeutic approach to potentiate the existing treatments against a very aggressive malignancy as multiple myeloma. Copyright © 2016 John Wiley & Sons, Ltd.